Scarica l'app Stockscreener
16.67
4.58%
-0.80
Pre-mercato:
17.67
1.00
+6.00%
Precedente Chiudi:
$17.47
Aprire:
$18.53
Volume 24 ore:
172.18K
Relative Volume:
1.92
Capitalizzazione di mercato:
$153.37M
Reddito:
-
Utile/perdita netta:
$-81.17M
Rapporto P/E:
-1.6449
EPS:
-10.1344
Flusso di cassa netto:
$-82.84M
1 W Prestazione:
+2.05%
1M Prestazione:
-4.42%
6M Prestazione:
-73.64%
1 anno Prestazione:
-72.65%
Intervallo 1D:
$16.25
$19.03
Intervallo di 1 settimana:
$16.25
$20.11
Portata 52W:
$11.13
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Nome
Korro Bio Inc
Settore
Industria
Telefono
617-468-1999
Indirizzo
60 FIRST STREET, CAMBRIDGE
Confronta KRRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
16.67 | 153.37M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-16 | Iniziato | Chardan Capital Markets | Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Raymond James | Strong Buy |
| 2024-08-14 | Iniziato | William Blair | Outperform |
| 2024-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2024-02-27 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-10 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-01-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-22 | Iniziato | B. Riley Securities | Buy |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-10-28 | Iniziato | Cowen | Outperform |
| 2019-10-28 | Iniziato | Goldman | Buy |
| 2019-10-28 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Korro Bio Inc Borsa (KRRO) Ultime notizie
Cantor Fitzgerald sets $74 target on Korro Bio stock with Overweight rating - Investing.com
Korro Bio (NASDAQ:KRRO) Research Coverage Started at Chardan Capital - Defense World
Chardan sets $25 target on Korro Bio stock with Buy rating - Investing.com Australia
Chardan Capital Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - Nasdaq
Chardan Initiates Korro Bio at Buy With $25 Price Target - marketscreener.com
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Korro Bio, Inc. (NASDAQ:KRRO) Shares Bought by Wellington Management Group LLP - Defense World
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Buy” by Brokerages - Defense World
KLP Kapitalforvaltning AS Purchases New Position in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Kemi Olugemo '87 Named Chief Medical Officer at Korro Bio - UMass Lowell
Raymond James Financial Inc. Purchases New Shares in Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio appoints new Chief Scientific Officer By Investing.com - Investing.com South Africa
Korro Appoints Loïc Vincent, Ph.D., as Chief Scientific Officer - citybiz
Korro Bio appoints new Chief Scientific Officer - Investing.com
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - The Manila Times
RNA-Editing Pioneer Korro Bio Lands Elite CSO with 20+ Drug Development Success Record - Stock Titan
Swiss National Bank Acquires Shares of 10,000 Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro Bio: Promising Early Stage RNA Editing Company (NASDAQ:KRRO) - Seeking Alpha
Korro Bio reappoints CFO, names new principal accounting officer By Investing.com - Investing.com Canada
Korro Bio CFO Returns from Medical Leave - TipRanks
Korro Bio reappoints CFO, names new principal accounting officer - Investing.com
Korro Bio Inc Vineet Agarwal Ends Temporary Medical Leave As CFO - MarketScreener
HC Wainwright Has Negative Outlook for Korro Bio Q1 Earnings - The AM Reporter
Research Analysts Set Expectations for Korro Bio Q1 Earnings - Defense World
Korro Bio (KRRO) Gets a Buy from Piper Sandler - The Globe and Mail
Q1 Earnings Forecast for Korro Bio Issued By William Blair - Armenian Reporter
HC Wainwright Reiterates Buy Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Q1 Earnings Estimate for Korro Bio Issued By William Blair - Defense World
Royal Bank of Canada Has Lowered Expectations for Korro Bio (NASDAQ:KRRO) Stock Price - Defense World
Korro Bio Reports 2024 Financial Results and Progress - TipRanks
H.C. Wainwright maintains Buy rating on Korro Bio stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy rating on Korro Bio stock - Investing.com
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth - Investing.com Australia
Korro Bio’s SWOT analysis: RNA editing firm’s stock poised for growth By Investing.com - Investing.com South Africa
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? - Yahoo
RBC Cuts Price Target on Korro Bio to $95 From $105, Keeps Outperform, Speculative Risk - Marketscreener.com
Korro Bio, Inc. SEC 10-K Report - TradingView
Korro Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Korro Bio Reports Clean Safety Data in AATD Drug Trial, Secures $163M Runway - StockTitan
Korro Bio (KRRO) Projected to Post Earnings on Tuesday - Defense World
FDA grants orphan drug status to Korro’s AATD treatment By Investing.com - Investing.com Australia
Korro Bio gets FDA Orphan Drug tag (KRRO:NASDAQ) - Seeking Alpha
Korro Bio's Potential Antitrypsin Deficiency Treatment Receives US FDA Orphan Drug Designation - Marketscreener.com
FDA grants orphan drug status to Korro’s AATD treatment - Investing.com
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - The Manila Times
Breakthrough for Rare Disease: FDA Awards Special Status to Korro Bio's Novel RNA Treatment - StockTitan
Rhumbline Advisers Purchases 691 Shares of Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Korro to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Korro Bio Inc Azioni (KRRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
2.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):